Clinical trials: Vehicle
Actinic Keratosis, Squamous Cell Carcinoma
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
One of the main reasons for treating actinic keratoses (AK) is the wish to lower the risk of progression of AK to squamous cell carcinoma (SCC).
- Trial name
- NCT03115476
- Testing
- ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%, Vehicle gel
- Where
- 59 sites in United States, Canada and 4 more
- Volunteers
- 563 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
This single blind study is to primarily evaluate wearable devices and Observer Reported Itch Assessment in children to assess reduction of itch and night-time scratch in response to Crisaborole treatment vs.
- Trial name
- PAD (NCT05200403)
- Testing
- Crisaborole 2%, Vehicle treatment, Accelerometry device for children
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Boston University
Stroke, Acute
Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct…
- Trial name
- ESCAPE-NA1 (NCT02930018)
- Testing
- Nerinetide (NA-1), 2.6 mg/kg
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 1,105 people
- Sponsor
- NoNO Inc.
Eyes Dry Chronic
ESBA105 in Patients With Severe Dry Eye
The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01338610
- Testing
- ESBA105 ophthalmic solution, ESBA105 vehicle
- Where
- United States
- Volunteers
- 334 people
- Sponsor
- Alcon Research
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Thermal Burns
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
This study will be a two-arms study intending to demonstrate superiority of NexoBrid treatment over SOC in children with thermal burns.
- Trial name
- NCT02278718
- Testing
- NexoBrid, Standard of Care
- Where
- 36 sites in United States, Belgium and 12 more
- Volunteers
- 145 people
- Sponsor
- MediWound Ltd
Acne Vulgaris
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
- Trial name
- NCT01974323
- Testing
- Dapsone Gel, Dapsone Gel Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 2,238 people
- Sponsor
- Almirall, S.A.
Inflammation, Pain
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this study is to evaluate the safety and efficacy of loteprednol etabonate (LE) ophthalmic gel, 0.38% (BID)
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02208297
- Testing
- Loteprednol Etabonate Gel (BID), Vehicle Gel (BID)
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Bausch & Lomb Incorporated
Acne Vulgaris
A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel
This is a Phase 1/2a study. The purpose of Phase 1 was to evaluate the safety and tolerability of DRM01B Topical Gel in 6 healthy volunteers.
- Trial name
- NCT01936324
- Testing
- Olumacostat Glasaretil Gel, 7.5%, Olumacostat Glasaretil Gel, Vehicle
- Where
- 12 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Dermira, Inc.
Dry Eye Disease
IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease
Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.
- Trial name
- NCT06400459
- Testing
- IVW-1001 Ophthalmic Eyelid Wipe 0.1%, IVW-1001 Ophthalmic Eyelid Wipe 0.2%
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- IVIEW Therapeutics Inc.
Acquired Blepharoptosis
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an…
- Trial name
- NCT02436759
- Testing
- RVL-1201
- Where
- 14 sites in United States
- Volunteers
- 140 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in…
- Trial name
- NCT03908970
- Testing
- 1% OPA-15406
- Where
- Japan
- Volunteers
- 364 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Anesthesia
Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers
The purpose of this study is to determine if the topical application to cheek tissue of the combination of benzocaine and tetracaine has a longer duration of local anesthetic activity than benzocaine alone.
- Trial name
- NCT02908620
- Testing
- One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cetylite Industries
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon.
- Trial name
- NCT02688270
- Testing
- Vascana (0.9% nitroglycerin cream)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Covis Pharma S.à.r.l.
Breast Cancer
HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer
This will be a randomized, double blind, vehicle-controlled evaluation of the effectiveness and safety of HylaCareTM. The study will employ the patient as her own control, a commonly used method for the evaluation of topical…
- Trial name
- NCT02165605
- Testing
- HylaCare
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Texas Southwestern Medical Center
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Bacterial Vaginosis
Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
This research study is being done to compare the safety and efficacy of GDC-229 (test drug) against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to establish that these two drugs work better than…
- Trial name
- NCT03091777
- Testing
- GDC-229, Metronidazole Vaginal Gel 0.75%
- Where
- United States
- Volunteers
- 871 people
- Sponsor
- Balmoral Medical company
Rosacea, Erythema
AGN-199201 for the Treatment of Erythema With Rosacea
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT01735201
- Testing
- AGN-199201 Dose A, AGN-199201 Dose B, AGN-199201 Dose C
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Safety and Efficacy Study of a Eye Drop for Eye Allergy
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
- Trial name
- NCT00889330
- Testing
- alcaftadine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vistakon Pharmaceuticals
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00691002
- Testing
- Calcipotriol plus hydrocortisone (LEO 80190), LEO 80190 Vehicle, Hydrocortisone
- Where
- 11 sites in Croatia, Germany and 2 more
- Volunteers
- 1,245 people
- Sponsor
- LEO Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.